May 22, 2017 2:10 PM ET


Company Overview of Premune AB

Company Overview

Premune AB, an animal health company, develops treatments for allergies, inflammatory bowel diseases, and other immune disorders in pets worldwide. Its developments are targeting problem areas in veterinary medicine. The company was founded in 2009 and is based in Stockholm, Sweden.

Kungsgatan 3 vån 4

Stockholm,  111 43


Founded in 2009


46 7 60 26 52 69

Key Executives for Premune AB

Co-Founder and Chief Executive Officer
Chief Operating Officer
Head of Licensing & Regulatory Affairs and Director
Age: 64
Head of Clinical Development
Head of Regulatory Affairs
Compensation as of Fiscal Year 2016.

Premune AB Key Developments

Premune Signs Licensing Agreement with Innovet Italia

Premune AB and Innovet Italia s.r.l. have signed an exclusive licensing agreement for six additional products, targeting three key areas in companion animal well-being. Premune and Innovet Italia are animal health companies based in Sweden and Italy, respectively. The extended product range includes Retopix(R) Spray, Retopix(R) Fluid, and Retopix(R) Oto (skin care), Normalia (R) (support of gut function) and Oculvet(R) Wipes and Oculvet(R) Drops (eye care). America. The expanded collaboration gives Premune exclusive marketing rights for key European countries, with the option to expand to other geographies including North America.

Premune Appoints Ed Torr as Head of Business Development and Commercial Operations

Premune announced the appointment of Ed Torr as Head of Business Development and Commercial Operations, effective September 7, 2015. Mr. Torr, who will be based in the UK, will oversee Premune's commercialization and business development efforts as the company prepares for its initial product launches. Ed brings more than 30 years of experience in animal health with senior leadership roles in some of the most prominent animal health companies in Europe including ICI, Coopers Animal Health, Alfa Laval Agri and Dechra Pharmaceuticals PLC. He was an executive director of Dechra Pharmaceuticals PLC from 2000-2014 during which time he had responsibility for business development, manufacturing and product development, Dechra Veterinary Products Europe and geographical expansion.

Premune AB Enters into Licensing Agreement with Innovet Italia s.r.l

Premune AB and Innovet Italia s.r.l. have entered into an exclusive licensing agreement for Redonyl (R) Ultra. Redonyl (R) Ultra is a nutritional supplement based on PEA-um (R) (ultramicronized palmitoylethanolamide) to support healthy skin in dogs and cats.

Similar Private Companies By Industry

Company Name Region
Abera Bioscience AB Europe
AddBIO AB Europe
Adenovir Pharma AB Europe
Affibody Medical AB (publ) Europe
Akinion Pharmaceuticals AB Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Premune AB, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at